Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus gemcitabine/cisplatin in first-line unresectable biliary tract carcinoma
ChiCTR2400083868Phase 4Not yet recruiting
- Sponsor
- Tangshan Central Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more, sponsored by Tangshan Central Hospital. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2400083868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083868.